

DAY 1 • THURSDAY, SEPTEMBER 24

6:30 am – 5:45 pm	Registration and Information • Harbor Foyer
7:00 am – 7:45 am	BREAKFAST • Industry Sponsored Product Theater • Harbor DEF
SESSION 1: PROSTATE IMAGING	
8:00 am – 8:05 am	Welcome Remarks
8:05 am – 8:25 am	Prostate MRI in 2026: Marks and Misses <i>Ayetkin Oto, MD</i>
8:25 am – 8:40 am	Not All MRIs Are Created Equal: The Hidden Variability of mpMRI <i>Sadhna Verma, MD</i>
8:40 am – 8:50 am	Discussion
8:50 am – 9:00 am	Precision Diagnostics: The Next Generation of MRI-Guided Prostate Biopsy <i>Peter Pinto, MD</i>
9:00 am – 9:10 am	PSMA PET: Precision Imaging or Precision Overdiagnosis?
9:10 am – 9:25 am	Signal or Noise? Rethinking Intraprostatic Tracer Uptake in PSMA Imaging <i>Nicholas Feinberg, MD</i>
9:25 am – 10:00 am	Panel Discussion: Smarter Selection for Screening and Diagnosis with Imaging and Biomarkers Moderator: <i>Minhaj Siddiqui, MD</i> Panelists: <i>Matthew Cooperberg, MD, Ayetkin Oto, MD, Peter Pinto, MD, Pawel Rajwa, MD, PhD, Abhinav Sidana, MD, MPH</i>
10:00 am – 10:30 am	BREAK • Harbor GHI
SESSION 2: ARTIFICIAL INTELLIGENCE	
10:30 am – 10:45 am	Artificial Intelligence and Prostate Cancer <i>Pawel Rajwa, MD, PhD</i>
10:45 am – 11:00 am	Bridging Radiologic Interpretation and Urologic Insight with AI in Prostate Imaging/Segmentation <i>Ayetkin Oto, MD</i>
11:00 am – 11:05 am	Discussion
11:05 am – 11:20 am	Can AI Assess Surgical Skill? Operative Video to Outcomes <i>Andrew Hung, MD</i>
11:20 am – 11:35 am	Your Next Patient is Using AI - Are You? <i>Giovanni Cacciamani, MD</i>
11:35 am – 11:45 am	Discussion
11:45 am – 12:20 pm	KEYNOTE LECTURE: From Assistance to Autonomy: Building Intelligent Surgical Robots <i>Michael Yip, PhD</i>
12:20 pm – 12:30 pm	Discussion
12:30 pm – 1:30 pm	LUNCH • Industry Sponsored Product Theater • Harbor DEF
1:30 pm – 5:45 pm	ADVANCED PROSTATE CANCER MASTERCLASS FOR UROLOGISTS
1:30 pm – 1:50 pm	Advanced Prostate Cancer: Key Concepts, Terminology, and Guideline Overview <i>Ben Martin, MD</i>
1:50 pm – 2:10 pm	Integrating Systemic Therapy into Localized Prostate Cancer Care <i>Pawel Rajwa, MD, PhD</i>
2:10 pm – 2:30 pm	Local and Metastasis-Directed Therapy in the Era of Systemic Intensification <i>Parthiv Mehta, MD</i>
2:30 pm – 2:40 pm	Discussion
2:40 pm – 3:00 pm	Targeting the Androgen Axis: Therapeutic Agents and Adverse Effects <i>Ben Martin, MD</i>
3:00 pm – 3:20 pm	Point Counterpoint: 73 yo male with denovo mCSPC, GG4, 5 bone mets seen on PSMA PET ADT+ ARPI <i>Justin Cohen, MD</i> ADT ARPI+ Docetaxel <i>Sharon Choi, MD</i>
3:20 pm – 3:30 pm	Discussion
3:30 pm – 4:00 pm	BREAK • Harbor GHI

DAY 1 • THURSDAY, SEPTEMBER 24 *continued*

4:00 pm – 4:15 pm	Genetic Testing and Impact on Treatment Selection <i>Justin Cohen, MD</i>
4:15 pm - 4:45 pm	Panel Discussion: Management of Low Volume PSMA Positive mets <i>Moderator: Ben Martin, MD</i> <i>Panelists: Nicholas Feinberg, MD, Abhinav Sidana, MD, MPH, Sharon Choi, MD</i>
4:45 pm – 4:55 pm	Parp Inhibitors for Prostate Cancer <i>Pawel Rajwa, MD, PhD</i>
4:55 pm – 5:15 pm	Radioligands in Advanced Prostate Cancer Management: Future Frontiers
5:15 pm – 5:35 pm	Emerging Therapeutic Targets in Prostate Cancer <i>Sharon Choi, MD</i>
5:35 pm – 5:40 pm	Discussion
5:40 pm – 5:45 pm	Conclusion <i>Ben Martin, MD</i>

DAY 2 • FRIDAY, SEPTEMBER 25

7:00 am – 6:00 pm	Registration and Information • Harbor Foyer
7:15am – 7:45 am	BREAKFAST • Industry Sponsored Product Theater • Harbor DEF
BPH MANAGEMENT COURSE	
SESSION 1: BPH Didactics – Updates, Technologies & Patient Selection <i>Moderators: John Michael DiBianco, MD, Bilal Chughtai, MD, Kevin Zorn, MD, Joel Funk, MD</i>	
8:00 am – 8:05 am	Welcome and Speaker Introductions <i>John Michael DiBianco, MD</i>
8:05 am – 8:15 am	BPH in 2026: Guidelines, Updates & What's New <i>Bilal Chughtai, MD,</i>
8:15 am – 8:25 am	MIST in 2026: Patient Selection & Practical Considerations <i>Kevin Zorn, MD</i>
8:25 am – 8:35 am	Surgical BPH: Patient Selection & Practical Considerations <i>Joel Funk, MD</i>
8:35 am – 8:40 am	Discussion
SESSION 2: Interactive Case Discussions – Challenging BPH Scenarios <i>Moderators: Joel Funk, MD, Bilal Chughtai, MD, Kevin Zorn, MD, Karla Witzke, DO, Bristol Whiles, MD</i>	
8:40 am – 9:20 am	Case 1: BPH + Prostate Cancer — Combined or Sequential Treatment? Case 2: Retention after Focal Therapy Case 3: Small Prostate (30g) — Unique Challenges Case 4: Younger Patient with BPH — Preserving Sexual Function Case 5: Large Prostate (>100g) — MIST vs. Surgery
SESSION 3: Practical BPH Development <i>Moderators: John Michael DiBianco, MD</i>	
9:20 am – 9:30 am	Staying “Up-To-Date” in a Busy Urology Practice <i>Karla Witzke, DO</i>
9:30 am – 9:40 am	Beginning a HoLEP Practice <i>Bristol Whiles, MD</i>
9:40 am – 9:50 am	Advances in HoLEP: MiLEP <i>Zham Okhunov, MD</i>
9:50 am – 10:00 am	Discussion
10:00 am – 10:05 am	Conclusions & Closing Remarks <i>John Michael DiBianco, MD</i>
10:05 am – 10:30 am	BREAK • Harbor GHI

DAY 2 • FRIDAY, SEPTEMBER 25 *continued*

BPH LIVE HANDS-ON LAB* • Mission Beach ABC	
10:30 am – 12:00 pm	Live Hands-on Lab*
	MIST Stations (<i>Karla Witzke, DO, Bilal Chughtai, MD, Kevin Zorn, MD</i>)
	Enucleation Stations (<i>Zham Okhunov, MD, Joel Funk, MD, Bristol Whiles, MD</i>)
12:00 pm – 1:00 pm	LUNCH • Industry Sponsored Product Theater • Harbor DEF
SESSION 3: INTRODUCTION TO FOCAL THERAPY	
1:00 pm – 1:15 pm	Rethinking the Rationale for Focal Therapy and Prostate Ablation <i>Zachary Feuer, MD</i>
1:15 pm – 1:30 pm	Patient Selection: Are All Intermediate Risk Cancers Candidates for Ablation? <i>Geoff Sonn, MD</i>
1:30 pm – 1:45 pm	Beyond MRI: The Value of Alternative Imaging in Patient Selection <i>Aditya Bagrodia, MD</i>
1:45 pm – 1:55 pm	Discussion
1:55 pm – 2:10 pm	Getting the Right Tissue: Optimizing Biopsy for Decision-Making <i>Abhinav Sidana, MD, MPH</i>
2:10 pm – 2:25 pm	Genomic/AI Risk Classifiers in Focal Therapy Selection <i>Matthew Cooperberg, MD</i>
2:25 pm – 2:30 pm	Discussion
2:30 pm – 3:00 pm	FTS LECTURE: Gleason 6 'Cancer' and Implications for Focal Therapy <i>Scott Eggener, MD</i>
3:00 pm – 3:30 pm	BREAK • Harbor GHI
SESSION 4: FOCAL THERAPY TREATMENT	
3:30 pm – 4:00 pm	Panel Discussion: Multi-Disciplinary Tumor Board in Focal Therapy: Patient and Treatment Selection <i>Moderator: Kara Watts, MD</i> <i>Panelists: Zachary Feuer, MD, Scott Eggener, MD, Sri Vourganti, MD, Geoff Sonn, MD, Arvin George, MD, Soroush Rais-Bahrami, MD</i>
4:00 pm - 4:20 pm	Strengths and Limitations of Ablative Technologies <i>Sri Vourganti, MD</i>
4:20 pm – 4:30 pm	What is the Optimal Margin for Treatment? <i>Kara Watts, MD</i>
4:30 pm – 4:35 pm	Discussion
4:35 pm – 5:25 pm	BALLOON DEBATE 82yo M Gleason 4+3 High Volume, Higher Volume GG1 Other Side, High Genomic Risk, PSA 14, 52g Prostate, LUTS Mild <i>Moderator: Abhinav Sidana, MD, MPH</i>
	Hemiablation – <i>Peter A. Pinto, MD</i>
	Active Surveillance/Watchful Waiting <i>Matthew Cooperberg, MD</i>
	Radiation Therapy (with/without ADT) <i>Parthiv Mehta, MD</i>
	Whole Gland Ablation <i>Geoff Sonn, MD</i>

DAY 2 • FRIDAY, SEPTEMBER 25 *continued*

5:30 pm – 6:00 pm	POSTER SESSION (non-cme) • Harbor Foyer <i>Moderators/Judges: Sandeep Gurram, MD, Kara Watts, MD</i>
Poster 01	Feasibility and Safety of Combined Cryoablation and HoLEP: A Pilot Study for Management of Prostate Cancer and BPH <i>Nabila Reem Khondakar, MD</i>
Poster 02	24-Month Outcomes from the PRESERVE Trial: Irreversible Electroporation Ablation for Intermediate-Risk Prostate Cancer <i>Jonathan Fainberg, MD, MPH</i>
Poster 03	Pre-Treatment High-Risk Decipher Category Predicts Recurrence After Primary Focal Ablation <i>Preston C. Sprenkle, MD</i>
Poster 04	Integrating Restriction Spectrum Imaging into Prostate MRI for Focal Therapy Planning: A Single-Center Experience <i>Preston C. Sprenkle, MD</i>
Poster 05	Serial PSA and Multiparametric MRI Each Associate with Biopsy-Proven Recurrence After MRI-Guided Transurethral Ultrasound Ablation (TULSA) But Are Insufficient to Replace Protocol Biopsy <i>Aziz Shaaban</i>
Poster 06	Single Versus Multiple Biopsies Before Focal Therapy and Recurrence Risk in Localized Prostate Cancer <i>Alejandro Calvillo-Ramirez</i>
Poster 07	Correlation of Six-Month MRI with In-field Biopsy After Water Vapor Ablation: Initial Results from the VAPOR 2 Study and VAPOR 2 Study Group <i>Arvin George, MD</i>
Poster 08	Comparison of Ginsburg, MUSIC and 10-core Transperineal Biopsy Template Systems in Detecting Clinically Significant Prostate Cancer <i>Jorge Arias</i>
Poster 09	Quantitative MRI EPE Score Models for Predicting Extraprostatic Extension and Adverse Pathology: Implications for Focal Therapy Patient Selection <i>Hangcheng Fu, MD</i>
Poster 10	Association of IsoPSA Categorization with PI-RADS Lesions and Biopsy Pathology in Men Undergoing Prostate Cancer Evaluation <i>Mary Namugosa-Makumbi MD</i>
Poster 11	A Novel Needle and Tissue-transfer System Versus Standard of Care for Prostate Biopsy Core Quality and Cancer Detection <i>Eric Gwynn, MD</i>
WELCOME RECEPTION 5:30 PM – 7:00 PM	

DAY 3 • SATURDAY, SEPTEMBER 26

6:45 am – 4:10 pm	Registration and Information • Harbor Foyer
7:00 am – 8:00 am	BREAKFAST • Industry Sponsored Product Theater • Harbor DEF
SESSION 5: FOCAL THERAPY SURVEILLANCE AND CHALLENGES	
8:00 am – 8:15 am	Can Focal Therapy Treatment Planning Tools Optimize Outcomes? <i>Arvin George, MD</i>
8:15 am – 8:25 am	Surveillance After Focal Therapy <i>Sandeep Gurram, MD</i>
8:25 am – 8:40 am	After the Burn: Interpreting Imaging Following Prostate Ablation <i>Sadhna Verma, MD</i>
8:40 am – 8:50 am	Discussion
8:50 am – 9:00 am	Guidelines Perspectives on Prostate Ablation <i>Soroush Rais-Bahrami, MD</i>
9:00 am – 9:10 am	Perspectives on Guidelines on Prostate Ablation <i>Abhinav Sidana, MD, MPH</i>

DAY 3 • SATURDAY, SEPTEMBER 26 *continued*

9:10 am – 9:30 am	Oral Abstract Presentations <i>Moderator: Sandeep Gurram, MD</i>
9:10 am	Office-Based Targeted Laser Ablation for Prostate Cancer: One-Year Oncologic and Functional Outcomes <i>Christian R. Lee</i>
9:15 am	PSMA-PET Detects Disease Not Visualized on Prostate MRI and Increases Confidence in Treatment Decision among Focal Therapy Candidates: Results from a Clinical Trial <i>Aaron Abrams</i>
9:20 am	Focal HDR Brachytherapy for Prostate Cancer: Minimizing Side Effects with Effective Local Control <i>Kaitlyn Lee</i>
9:30 am – 10:00 am	BREAK • Harbor GHI
10:00 am – 12:15 pm	Hands-on TP and Fusion Guided Ablation • Mission Beach ABC
12:15 pm – 1:00 pm	LUNCH • Industry Sponsored Product Theater • Harbor DEF
SESSION 6: SURVIVORSHIP AND BEYOND	
1:00 pm – 1:20 pm	Patterns of Failure After Focal Therapy and Their Management <i>George Schade, MD</i>
1:20 pm – 1:35 pm	Salvage Radical Therapy After Focal Therapy Recurrence <i>Michael Liss, MD</i>
1:35 pm – 2:10 pm	Case Discussions: Recurrence and Management <i>Moderator: George Schade, MD</i> <i>Panelists: Arvin George, MD, Abhinav Sidana, MD, MPH, Krishnanath Gaitonde, MD</i>
2:10 pm – 2:25 pm	Clinical Trials in Focal Therapy (in the last 12 months) <i>Furkan Dursun, MD</i>
2:25 pm – 2:40 pm	Is Prostate Ablation an Option for Treatment of Select Higher Risk Prostate Cancers? <i>Deepika Reddy, MD</i>
	Addressing the Critiques of Focal Therapy
2:40 pm – 2:50 pm	Prostate Cancer is Multifocal (index lesion) <i>Krishnanath Gaitonde, MD</i>
2:50 pm – 3:00 pm	FT Has Poor Local Control and High Retreatment Rates <i>Arvin George, MD</i>
3:00 pm – 3:10 pm	Lack of Level 1 Evidence / Long Term Comparative Outcomes <i>George Schade, MD</i>
3:10 pm – 3:20 pm	Salvage Treatment Complexity <i>Abhinav Sidana, MD, MPH</i>
3:20 pm – 3:30 pm	Discussion
3:30 pm – 3:50 pm	Beyond Treatment: Lifestyle Choices That Impact Prostate Cancer <i>Geo Espinosa, ND, FMCP-M</i>
3:50 pm – 4:00 pm	CPT Updates: Billing and Reimbursement for Fusion, Transrectal, and Transperineal Biopsy <i>Arvin George, MD</i>
4:00 pm – 4:10 pm	Conclusion